Ilika updates on trading, Stereax manufacturing, and Goliath product development

Ilika Plc

Ilika plc (LON:IKA), an independent global expert in solid-state battery technology, has provided updates on trading, Stereax® manufacturing, and Goliath product development, as well as notice of its full year results for the year ended 30 April 2024.

Trading Update for FY24

Unaudited trading for the year ended 30 April 2024 has been in line with management expectations. The Company expects to announce revenues of approximately ÂŁ2.1m (2023: ÂŁ0.7m), and an EBITDA loss excluding share-based payments of around ÂŁ4.5m (2023: EBITDA loss of ÂŁ7m). Cash and cash equivalents at the period end were ÂŁ11.9m (30 April 2023: ÂŁ15.8m).

Operational Update

During the Period, significant progress was made with transferring manufacturing to Cirtec Medical LLC under the licence of Ilika’s thin-film Stereax miniature solid-state batteries for powering medical devices and industrial wireless sensors in specialist environments.

In addition, the Company achieved significant milestones in developing its large-format Goliath cells for electric vehicles and cordless appliances. Recently the Company also announced that Agratas, a Tata Group global battery business, has joined its SiSTEM grant funded scale up activity.

In parallel to joining the SiSTEM project, Ilika and Agratas have entered into a 12-month agreement that will facilitate interactions between the companies to support Ilika’s journey to its D8 (50Ah, chemistry frozen) development milestone in H1 2025 – which will underpin licencing opportunities, alongside exploring wider collaboration opportunities between the two parties.

On 10 May 2024, Ilika also announced a capital raising activity comprising of a conditional placing of new ordinary shares, raising gross proceeds of ÂŁ1.7m, and an open offer for new ordinary shares, with the intention to raise up to an additional ÂŁ1.7m, to provide additional support for the development of its Goliath solid-state battery.

Notice of Results

The Company expects to announce its audited full year results for the year ended 30 April 2024 on Thursday 11 July 2024. 

Analyst Briefing

The management team will be hosting an in-person analyst briefing on the day, Thursday 11 July 2024, at 9.30am. Analysts who wish to attend should contact Nick Rome at Walbrook PR on +44(0)20 7933 8780 or email [email protected] to register.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika positions solid state batteries for the future of implantable neurostimulation

Ilika’s Stereax solid state battery technology supports the development of smaller, safer and more practical implantable neurostimulation devices for emerging medical applications.

Ilika advances manufacturing readiness for solid-state batteries

Ilika’s collaboration with UKBIC shows how manufacturing validation is helping move its Goliath pouch cell technology closer to commercial readiness.

Ilika reports first Stereax revenues and Goliath progress

Ilika expects FY26 revenue of approximately ÂŁ1.1m, including first commercial Stereax electrode sales, with Goliath evaluation activity expanding across automotive, defence and e-bike applications.

Defence battery demand highlights strategic opening for Ilika

Ilika highlights how rising defence and energy security demands are expanding the commercial opportunity for advanced battery technologies across military and infrastructure markets.

Ilika to showcase Stereax batteries to medical device manufacturers

Ilika’s Stereax batteries will be represented at Medical Technology Ireland 2026, giving the company direct exposure to medical device manufacturers and suppliers.

Search